Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

NIH 2OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Melanoma 93Carcinoma, Non-Small-Cell Lung 46Neoplasms 33Carcinoma, Renal Cell 24Neoplasm Metastasis 16Colorectal Neoplasms 13Carcinoma, Hepatocellular 12Small Cell Lung Carcinoma 9Prostatic Neoplasms 9Lung Neoplasms 9Diabetes Mellitus, Insulin-Dependent, 12 9Advanced Cancer 9Squamous Cell Carcinoma of Head and Neck 8Uveal Melanoma 7Stomach Neoplasms 7Skin Neoplasms 7Mesothelioma 7Kidney Neoplasms 7Carcinoma, Transitional Cell 7Recurrence 6Pancreatic Neoplasms 6Liver Neoplasms 6Triple Negative Breast Neoplasms 5Sarcoma 5Ovarian Neoplasms 5Head and Neck Neoplasms 5Endometrial Neoplasms 5Breast Neoplasms 5Uterine Cervical Neoplasms 4Solid Tumor 4

Interventions

nilotinib 50Imatinib Mesylate 48Dasatinib 25bosutinib 18asciminib 17ponatinib 10Homoharringtonine 5Cytarabine 4olverembatinib 3Interferon-alpha 3Decitabine 3tozasertib 2peginterferon alfa-2a 2flumatinib 2fludarabine phosphate 2ON 01910 2Mycophenolic Acid 2Melphalan 2Interferon alpha-2 2Filgrastim 2Cyclophosphamide 2Bone Marrow Transplantation 2BID protein, human 2Azacitidine 24-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide 2vosaroxin 1troxacitabine 1triciribine 1terameprocol 1sonidegib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × Ipilimumab × Clear all
NCT00732186 2016-02-17

Study of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid Leukemia

Bristol-Myers Squibb

Phase 1 Withdrawn
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡